Eli Lilly and Company

Science has been our calling from the beginning. Colonel Eli Lilly founded the company in 1876 and charged employees to “take what you find here and make it better and better.” More than 147 years later, we remain committed to his vision through every aspect of our business and the people we serve, starting with discovering the best treatments for those who take our medicines and extending to health care professionals, employees and the communities in which we live. Moreover, you can also count on the team at Lilly to be incredibly civic-minded, supporting our communities through philanthropy, volunteerism, and a creative and innovative can-do spirit.

When you’re on a mission to do what’s never been done before, you seek people willing to challenge the status quo of medicine. Those willing to relentlessly pursue what’s next, all in the name of health above all. #WeAreLilly

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
893 S Delaware St
Indianapolis, IN 46285
  • Featured Employer
Exceptional people with an
extraordinary purpose.
Our values and commitment
have guided our success
for over 140 years.
We are Lilly
Why do our employees love coming to work each and every day? Here’s what they have to say.
  • “Opportunity for growth is actually the biggest reason that I ended up hiring into Lilly.”
    Kavita - Associate Director, Packaging Operations
  • “Lilly worked bery hard to be able to allow me to settle into my role, but they also had a great deal of consideration for my life outside of work.”
    Adrian - Associate Director, IDM
  • “What we do matters, it matters to the people that we interact with. It matters to people in our families and it matters to people around the world.”
    Cecile - Sr Director, Design Hub Foundations
39,000 global employees coming together from diverse backgrounds to create medicines that make life better for people around the world. Get to know us through our Powered by Purpose series.
NEWS
Despite the greenlight from the U.S. Food and Drug Administration as an emergency treatment, there are some questions about how effective the treatment will actually prove to be due to labeling limitations.
Jeff Dage, Ph.D., senior research adviser at Eli Lilly and Company, presented the case for P-tau in blood as an accurate biomarker.
FDA
Bamlanivimab, an intravenous treatment, should be administered as soon as possible after a positive COVID-19 test and within 10 days of symptom onset.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 10, 2020.
It was relatively quiet in terms of COVID-19-related clinical trials, but there was still quite a bit of news for trials involving other indications. Here’s a look.
Eli Lilly is continuing their other trial in mild-to-moderate COVID-19 patients and stated they “remain confident … that bamlanivimab monotherapy may prevent progression of disease for those earlier in the course of COVID-19.”
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 27, 2020.
UCB is investing more than £1 billion over five years to expand its research and development capabilities in the U.K., which will include a transition to a newly acquired 47-acre R&D campus from Eli Lilly located in Windlesham, Surrey.
Eli Lilly is betting on a new approach to axonal degeneration, announcing a definitive agreement to acquire Disarm Therapeutics, a privately-held biotech company committed to solving this mystery.
JOBS
IN THE PRESS